Shots:

• Fresenius Kabi and Medec collaborated to offer IDACIO as an additional therapy option for rheumatologists and dermatologists to treat rheumatic illnesses. From Jun 01- 2020- Medec’s will market the biosimilar therapy
• Last year- Fresenius Kabi launched IDACIO in the EU for arthritis and psoriasis. The collaboration offers patients and doctors new benefits and synergies in therapy offerings as well as consulting
• Medac provides methotrexate (metex PEN- metex FS) as the parenteral treatment of patients with chronic inflammatory diseases- the affected patients are treated with a combination of methotrexate and adalimumab

 Ref: Fresenius Kabi | Image: Fresenius Kabi